U.S. stock insider trading | Repligen disclosed two insider transactions on March 5.

K-LinePoet · 2026-04-06T21:32:03+00:00

Repligen (RGEN) disclosed internal related-party transactions on March 5, 2026. Executive Bylund James sold 62 shares on March 4. Recently, several executives and directors, including RALF KURIYEL and Jason K. Garland, have also sold shares. Repligen focuses on the supply of biopharmaceutical products, covering multiple areas such as new drug development and clinical trials.

K-LinePoet

2026-04-06 21:32:03

Abstract generation in progress

On March 5, 2026, Repligen (RGEN) disclosed two company insider transactions. On March 4, 2026, executive Bylund James sold 62 shares.

【Recent Insider Trading】

Disclosure Date	Title	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/US$	Total Amount/US$
March 5, 2026	Executive	Bylund James	March 4, 2026	Sell	62	125.84	7802.08
March 5, 2026	Executive	KURIYEL RALF	March 4, 2026	Sell	42	125.84	5285.28
March 3, 2026	Executive	Garland Jason K	March 2, 2026	Sell	715	124.97	89.4k
March 3, 2026	Executive	Bylund James	February 27, 2026	Sell	1478	128.73	190.3k
March 3, 2026	Director	Loeillot Olivier	March 2, 2026	Sell	1610	124.97	201.2k
March 3, 2026	Director	Loeillot Olivier	February 27, 2026	Sell	344	128.73	44.3k
March 3, 2026	Director	Hunt Anthony	March 2, 2026	Sell	9897	124.97	1.24M
March 3, 2026	Executive	Garland Jason K	February 27, 2026	Sell	327	128.73	42.1k
March 3, 2026	Executive	Bylund James	March 2, 2026	Sell	2433	124.97	304.1k
March 3, 2026	Executive	Douglass Brian Robb	March 2, 2026	Sell	221	124.97	27.6k

【Company Profile】

Repligen Corporation is a leading supplier of key products for biopharmaceutical manufacturing. The company’s proteins, including Protein A, provide long-term supply and long-term contracts to important life science research companies, and it also sells directly to end users at the terminal stage of pharmaceutical processing and manufacturing chains. The company provides SecreFlo with professional bioresearch products for its latest drug. This drug has already been submitted to the U.S. Food and Drug Administration for approval and has received priority review, and the company has submitted a market authorization application to the European drug regulatory authority. SecreFlo is a company developing a new imaging agent for synthetic human hormone drugs, aimed at diagnosing pancreatitis and multiple potential pancreatic diseases.

The company is conducting research into two early-stage projects for rare central nervous system diseases—Friedreich’s ataxia and spinal muscular atrophy—which have entered Phase 1 of clinical trials. In addition, the company has obtained an additional licensing agreement for intellectual property from Bristol-Myers Squibb—under which the company can sell patents related to Abasupregirl at its real-price sales in the United States.

The company was founded in May 1981.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes